Personalis Q3 revenue up 23% to $18.2M; raises FY2023 guidance

Personalis, Inc.

2023-Q3 EPS reported -$1.71 revenue$53,806,000

Revenue $18.2M (+23% YoY); net loss $29.1M, EPS -$0.60 including $5.6M impairment.
Full-year 2023 revenue guidance raised to $73-74M (prior $70-72M); Q4 guided $19-20M.
Pharma/enterprise revenue $15.8M (+7% YoY); Natera contributed $7.9M.
TRACERx data: NeXT Personal up to 4x sensitivity vs other liquid biopsies; detects lung cancer 6-11 months before imaging.
Cash $120.7M; FY2023 cash usage <$70M vs $119M in 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Personalis, Inc. reported the third quarter ended September 30, 2023 results: revenue $18.2 million, net income $29.1 million, EPS $0.60. Guidance raised.

Period: the third quarter ended September 30, 2023
Revenue: $18.2 million
Net income: $29.1 million
EPS: $0.60
Guidance: raised
Result: reported results

Exact text from the filing

reference in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Personalis Reports Third Quarter 2023 Financial Results Increased third quarter revenue 23% to $18.2 million and increased full year guidance Presented data supporting Next Personal’s market leading sensitivity for cancer recurrence detection FREMONT, Calif. – November 7, 2023 –

View on SEC.gov

Browse all earnings releases →

Personalis, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-060202

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.